Stem cell therapy may help knees according to : citizensvoice

Article Tools Font size – + Share ThisQ: I read that you can use your own stem cells to rejuvenate worn-out knees. The intriguing thing about stem cells is that they have the ability to become any type of cell that the body needs. The cells used for stem cell injections in the knees are called mesenchymal stem cells, and they can differentiate into bone, fat or cartilage cells. In five of the studies, stem cells were given after surgery to the knee; in the other study, stem cells from a donor were administered without surgery. There may be benefit to stem cell injections for cartilage loss of the knees, but more data are needed.




Too often it restricts the heart's ability to fill properly between beats, disrupting rhythm and ultimately leading to heart failure. A cadre of scientists and companies is now trying to prevent or reverse cardiac damage by infusing a cocktail of stem cells into weakened hearts. One company, Melbourne, Australia–based Mesoblast, is already in late-stage clinical trials, treating hundreds of chronic heart failure patients with stem cell precursors drawn from healthy donors' hip bones. A randomized trial that includes a placebo group is scheduled to complete enrollment next year. Mesoblast's earlier-stage trials, published in 2015 in Circulation Research, found that patients who received injections of its cell mixture had no further problems related to heart failure.

£2m collaboration to focus on gene and cell therapy

£2m collaboration to focus on gene and cell therapy0 SHARESPosted: 14 August 2017 | Dr Zara Kassam (addiction Target Review) |A leading gene and cell Therapy group has announced a collaboration focusing on gene and cell therapy manufacturing..A leading gene and cell therapy group, has announced it has agreed to enter into a collaboration agreement with a consortium of partners, the agreement is a two-year £2 million collaboration project focused on gene and cell therapy manufacturing, co-funded by the UK's innovation agency, Innovate UK. The aim of the collaboration is to explore and apply novel advanced technologies to further evolve OXB's proprietary suspension LentiVector platform to deliver even higher quality vectors for both clinical and commercial use. The project aims to deliver tangible benefits to patients by shortening the time-to-clinic and time-to-market as well as to improve the cost and access of bringing novel gene and cell therapies to patients. "Collaborating on developing improved process analytic technologies with our partners will help drive productivity in viral vector manufacturing, accelerating the development of these transformative advanced therapies. We have the opportunity to both transform patients' lives and grow an industry in the UK that we can be proud of,"said Keith Thompson, Chief Executive Officer of Cell and Gene Therapy Catapult.


collected by :Lucy William

To follow all the new news about Health care